MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Alpha-synuclein"

  • 2019 International Congress

    Widespread distribution and abundant accumulation of alpha-synuclein oligomers in multiple system atrophy brain

    H. Sekiya, H. Kowa, H. Koga, M. Takata, W. Satake, N. Futamura, I. Funakawa, K. Jinnai, M. Kanagawa, K. Kobayashi, T. Toda (Kobe, Japan)

    Objective: To examine the distribution of alpha-synuclein (αSyn) oligomers as an early pathological change in multiple system atrophy (MSA) brains. Background: Although severe neuronal loss…
  • 2019 International Congress

    Evaluation of neuroprotection by human ENGRAILED-1 in a chronic AAV-hα-synuclein-A53T (AAV-A53T) rat model of Parkinson Disease

    A. Prochiantz, G. Porras, A. Simonnet, E. Pioli, C. Friedel, E. Bézard, A. Bousseau (Paris, France)

    Objective: Investigate the long-term neuroprotective effect  of a single bilateral injection of human ENGRAILED1 (hEN1) in a rat α-synuclein model of Parkinson Disease (PD). Background:…
  • 2019 International Congress

    Neuritic pathology in Parkinson’s Disease results from loss of anti-oxidant response activity

    S. Ryan, M. Stykel, C. Coackley, T. Ryan (Guelph, ON, Canada)

    Objective: To determine the link between α-syn accumulation and neuritic pathology in Parkinson’s Disease (PD). Background: Neurological dysfunction in PD is highly associated with pathological…
  • 2019 International Congress

    Role of microRNA-153 and -223 in Parkinson disease

    M. Cressatti, W. Song, L. Jawura, J. Galindez, O. Canie, A. Velly, M. Gornitsky, H. Schipper (Montreal, QC, Canada)

    Objective: To assess the therapeutic and diagnostic potential of microRNA (miR)-153 and miR-223 in mice and humans with parkinsonism. Background: Dysregulated miRNAs play a major…
  • 2019 International Congress

    A First in Human Study of PBT434, a Novel Small Molecule Inhibitor of Alpha-Synuclein Aggregation

    D. Stamler, M. Bradbury, C. Wong, E. Offman (Newark, CA, USA)

    Objective: To evaluate the safety, tolerability and pharmacokinetics of PBT434 in healthy volunteers. Background: PBT434 is a novel, small molecule inhibitor of alpha-synuclein aggregation. In…
  • 2019 International Congress

    Maladaptive Nigrovagal Neuronal Plasticity Causes Ascending Alpha-Synucleinopathy in a Novel Environmental Toxin Based Rat Model of Parkinsonism

    T. Subramanian, K. Le, S. Hojjatinia, K. Venkiteswaran, M. Subramanian, L. Anselmi, C. Bove, R. Travagli (Hershey, PA, USA)

    Objective: Test the hypothesis that unilateral chemogenetic inhibition of the nigrovagal pathway in the subthreshold Paraquat (P) + dietary lectin (L) exposure rat model of…
  • 2019 International Congress

    NILO-PD: A Phase 2A Study of Nilotinib in Patients with Advanced Parkinson’s Disease: Study Design and Status Update

    T. Simuni, B. Fiske, K. Merchant, C. Coffey, H. Matthews, R. Wyse, P. Brundin, D. Simon, M. Schwarzschild, D. Weiner, J. Adams, C. Venuto, L. Trusso, L. Baker, M. Kostrzebski, T. Ward, G. Rafaloff (Boston, MA, USA)

    Objective: To assess the safety and tolerability of nilotinib (150-300 mg once daily) in moderate/advanced Parkinson’s disease (PD). Background: Nilotinib is approved by the FDA…
  • 2019 International Congress

    The influence of gender, associated neurological disorder and motive for polysomnography (PSG) in the manifestations of REM sleep behaviour disorder (RBD)

    P. Bugalho, M. Salavisa (Lisbon, Portugal)

    Objective: To access the interrelation and relative influence of gender, associated neurological disorder and context of referral to PSG on the manifestations of  (RBD). Background:…
  • 2019 International Congress

    Long-Term Effects of LPS and Alcohol in Rats: A Model of Neuro-Degenerative Disease

    M. Schiess, M. Doursout, J. Campo, Z. Peng, A. Sundaresan, S. Umar (Lawrence, KS, USA)

    Objective: We postulate alterations of the intestinal barrier (or leaky guts) enhances inflammation, as well as the production of alpga (α)-synuclein which has characteristic pathological…
  • 2019 International Congress

    Impact of a high-fat diet on the behavior of A53T alpha-Synuclein Parkinson’s disease mice

    M. Temmel, V. Niederkofler, R. Rabl, H. Roemer, B. Hutter-Paier (Grambach, Austria)

    Objective: The aim of this project was to evaluate high-fat diet (HFD) induced behavioral alterations in the A53T alpha-Synuclein Parkinsons’s disease mouse model. Background: Besides…
  • « Previous Page
  • 1
  • …
  • 51
  • 52
  • 53
  • 54
  • 55
  • …
  • 70
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley